Halozyme Therapeutics, Inc. (HALO) 2016年年度报告「NASDAQ」.pdf

1、2016 ANNUAL REPORTAdvancingTherapeutics.EnhancingLives.Our Diversified PipelineOncology Pipeline and Product CandidatesBroad Range of Partnered and Proprietary ProductsProprietary Approved ProductENHANZE Collaboration Approved ProductsENHANZE Collaboration Product CandidatesCopyright 2017.Halozyme,I

2、nc.All rights reserved.All trademarks belong to their respective owners.Halozyme Therapeutics,Inc.11388 Sorrento Valley RoadSan Diego,CA 92121858-794-Our Diversified PipelinePRODUCT PIPELINEPRODUCT,COLLABORATION PRODUCTS AND PRODUCT CANDIDATESRocheRoche Total of 8 potential targetsBaxaltaPfizer Tota

3、l of 6 potential targetsJanssen Total of 5 potential targetsAbbVie Total of 9 potential targetsUndisclosedUndisclosedLilly Total of 5 potential targetsUndisclosedOncologyPancreatic CancerPhase 3HYLENEXrecombinant(hyaluronidase human injection)VariousAdjuvant for Sub-Q fluid delivery for dispersion&a

4、bsorption of other injected drugsU.S.ApprovedOncologyGastric/Non-Small Cell Lung CancerPhase 1OncologyVariousPreclinicalMABTHERA SC(rituximab)OncologyNon-Hodgkins Lymphona&Chronic Lymphocytic LeukemiaEU approved and other countries outside the U.S.Approved for CLL in EU.U.S.filing has been accepted

5、by FDAOncologyBreast Cancer(Eisai)Phase 1HERCEPTIN SC(trastuzumab)OncologyBreast Cancer EU approved and other countries outside U.S.PERJETA (pertuzumab)OncologyBreast CancerPhase 1daratumumab(DARZALEX)OncologyMultiple MyelomaPhase 1OncologyVariousPreclinicalTHERAPEUTIC AREARESEARCH FOCUS/INDICATIOND

6、EVELOPMENT STAGEOncology Pipeline and Product CandidatesBroad Range of Partnered and Proprietary ProductsProprietary Approved ProductENHANZE Collaboration Approved ProductsENHANZE Collaboration Product CandidatesImmunologyPrimary ImmunodeficiencyEU,U.S.,Puerto Rico and Australia approvedHYQVIA Immun